Share Twitter LinkedIn Facebook Email Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib.
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews] Multiple Myeloma 13 Mins Read